CML-paed II Registry
Author: Julia Dobke, Last modification: 2024/03/26 https://kinderkrebsinfo.de/doi/e231347
CML-paed II Registry | Protocol for standardised diagnostical procedures, registration und treatment recommandations for children and adolescents with Philadelphia positive chronic myeloic leukeamia |
---|---|
Disease | Chronic myeloic leukeamia (CML) |
Type | Prospective registry |
Problem / Objectives |
The patients are usually diagnosed at the GPOH centers (see list) according to guidelines and treated. The treatment takes place within the framework of the approval for both imatinib and in the meantime approved second-generation tyrosine kinase inhibitors dasatinib and nilotinib. The Medicines are not given for study reasons. The patients are independent of the registry in Treatment (already before and after). The register also does not result in any disadvantages for current and future therapies. |
Therapy / Study arms |
|
Inclusion Criteria |
|
Exclusion Criteria |
|
Recruitment | unlimited |
Status | 01.01.2016 - until further notice |
Principal Investigator | Prof. Dr. med. M. Metzler |
cml-paed@uk-erlangen.de | |
URL | https://www.kinderonkologie.uk-erlangen.de/forschung-und-lehre/cml-studie/formulare-und-downloads/ |
Contact |
CoordinatorProf. Dr. med. Markus Metzler Universitätsklinikum Erlangen Kinder- und Jugendklinik Loschgestr. 15 91054 Erlangen Telefon +49(0) 9131 85-33731 Fax +49(0) 9131 85-35742 cml-paed@uk-erlangen.de |
Participants | GPOH-centres |